

CURRICULUM VITAE PROF. MANGANO KATIA DOMENICA
(Drafted according to Articles 46 and 47 of Presidential Decree 28.12.2000, n. 445)

The undersigned Katia Domenica Mangano, born in Catania on 10/01/1975, resident in Catania via Bruno Monterosso, 16, aware, according to art. 76 of Decree 445/2000, that false statements, preparation or use of false documents are punishable under the penal code and special laws on the matter

DECLARE

PERSONAL INFORMATIONS

Name	Mangano Katia Domenica
Accademic role	Associate professor
Address	Via S.Sofia, 97 – Biological Tower – 95123, Catania
Mobile number	3393278353
E-mail	kmangano@unict.it
Nationality	Italian
Date of birth	[January 10 th , 1975]
Native language	ITALIAN
Other language	English: IELTS B2 level – April 2021

Dr. Katia Mangano is Associate Professor of General Pathology and Immunology at the Department of Biomedical and Biotechnological Sciences, University of Catania. She has been and continues to be a reviewer and part of the editorial committee of several journals.

Since 2000, Dr. Katia Mangano has been engaged in research activities in immunology, immunopharmacology, autoimmunity, and experimental oncology at the Laboratory of Immunopathology and Translational Immunopharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania. Her research focuses on studying the pathogenic mechanisms involved in these diseases in both animal models and humans, as well as evaluating the efficacy of new therapeutic approaches. This research line has led to collaborations with international pharmaceutical and biotechnological companies, resulting in numerous publications and a significant contribution to the advancement of preclinical and clinical development of the studied compounds. Notably, three of the compounds studied at the preclinical level, MP1032, HE3286, and VGX1027, have reached the clinical development stage, having successfully passed at least phase 1. The candidate's interest in a research line also

focused on technology transfer and the industrial valorisation of the compounds is demonstrated by the patent activity obtained.

This collaboration, along with other national and international research groups, has produced 105 publications in international scientific journals, achieving an h-index of 34 and 3.315 citations (Scopus 16/02/2026).

EDUCATION AND TRAINING

1998-1999	<u>Training</u> in Mycology and Bacteriology Laboratories at the Department of Microbiologies Sciences and Gynecological Sciences of the University of Catania, Italy
1999-2019	<u>Attendance</u> in Immunology Laboratory at the Department of Bio-medical Sciences of the University of Catania, Italy
17/07/2000	<u>Master degree</u> in Chemistry and Pharmaceutical Technologies at the Faculty of Pharmacy, University of Catania. Thesis title: “Immunosuppressive activity of Ruta chalepensis on a mouse model of induced autoimmune arthritis”
25/06/2001	<u>Qualification</u> for the professional practice of Pharmacist, University of Catania
2002-2004	<u>PhD</u> in Microbiological Disciplines at the University of Catania. Project title: “Immunotherapeutic effects of MIF inhibition in sepsis using specific low molecular weight inhibitors”
2017	<u>National scientific qualification</u> for associate professor - Sector 05/E3, Clinical biochemistry and clinical molecular biology
2018	<u>National scientific qualification</u> for associate professor - Sector 06/A2, General Pathology and Clinical Pathology
2023	<u>National scientific qualification</u> for full professor – Sector 06/A2 - General Pathology and Clinical Pathology

RESEARCH CONTRACT AND FELLOWSHIP

- 2000-2002: Fellowship Young Researcher Project – project title:” Studies on the effects of treatment with Interleukin-6 in Experimental Allergic Neuritis”
- 2004-16 Research Agreement with Cosmo Pharmaceuticals, Lainate (MI) performing in vitro and in vivo experiments of inflammatory intestinal and skin diseases, colon cancer, dependent androgen diseases, for the study of new pharmaceutical technologies
- 2005-2006 Research agreement with Department of Bio-medical sciences – Project title: “Evaluation of the immunomodulatory activity of human transferrin and its use in the therapy of autoimmune and inflammatory diseases”.
- 2007-2009 Research agreement with Department of Bio-medical sciences – Project title: “Study on the effects of nitric oxide (NO) and NO releasers on autoimmunity and cancer”.
- 2010 Research agreement with Department of Bio-medical sciences – Project title: “Effects of CORM (carbon monoxide releasing molecules) treatment in animal models of autoimmunity”.
- 2011-2012 Senior Fellowship FISM – Project title: “Epigenetic treatment with the hypomethylating compound 5-aza-2-deoxycytidine in animal models of multiple sclerosis”
- 2013-2014 Research Agreement with the Department of Biomedical and Biotechnological Sciences. Title of the research project: “In vitro and in vivo evaluation of some compounds with immunomodulatory/anti-inflammatory activity”
- 2015 Contract of occasional collaboration at the Department of Biomedical and Biotechnological Sciences in the project S.I.S.C.A. – POR FESR Sicilia 2007/2013, Dec. Di Finanz.: D.D.G. n. 759/3
- 2019- today Consultant for COSMO Pharmaceuticals
- 09/03/2021-09/05/2021 Consulting contract - PON FESR 2014/2020 II (SAFE DEMON) SAFE Driving by E-health MONitoring

ROLES OF RESPONSIBILITY AND TEACHING ABROAD

- 2019-2020 ERASMUS+ PROGRAM – KEY ACTION 1 STAFF MOBILITY | TEACHING ASSIGNMENTS (STA) - *Teaching* at the University of Granada (online due to COVID)
- 2020-2023 ERASMUS+ Key Action 2: Cooperation for innovation and the exchange of good practices. Capacity Building in the field of higher education. Role: Scientific *Responsible of the Unit*, University of Catania, BIOMETEC
- 22/11/2019- 12/10/2021 Coordinator of I level Master in Palliative Care and Pain Therapy
- 18/11/2022 – today Coordinator of II level Master in Palliative Care and Pain Therapy
- 2022-2023 Scientific responsible of a research project with Aileens Pharma srl, Nova Milanese, Italy
- 2022-2023 Scientific responsible of a research project with Medivis srl, Catania, Italy
- 22/01/2023- 25/01/2023 Teaching at Jimma University, Jimma, Ethiopia
8 hours of lessons on: Immunological Tolerance; Pathogenetic mechanisms of Autoimmunity; Autoimmunity and infections
- 26/01/2023- 28/01/2023 Teaching at Debre Markos University, Debre Markos, Ethiopia
8 hours of lessons on: Immunological Tolerance; Pathogenetic mechanisms of Autoimmunity; Autoimmunity and infections

PARTICIPATION IN INTERNATIONAL BOARDS OF SCIENTIFIC JOURNALS

From 2014 to date, Dr. Katia Mangano is reviewer for the following journals:

- Anti Infective Agents
- Archives of Biological Sciences
- Biomaterials
- Evidence-Based Complementary and Alternative Medicine
- Journal of Cellular Physiology
- Journal of Neuroimmunology
- Journal of Translational Medicine
- Medical Science Monitor
- Open Medicine

- Oncology Letters
- Molecules
- Molecular Medicine Report
- International Journal of Molecular Sciences

From 2015 to date she is a member of the editorial board of the journal Archives of Biological Sciences

DIDACTIC ACTIVITY

[2009-2011]

University of Catania

Contract professor

Teaching of Science of Sanitary Professions and HEALTH PROFESSIONS AND ASSISTANCE TECHNIQUES SCIENCES

[2011-2012]

University of Catania

Contract professor

Teaching of General and Clinic Pathology in the degree course of NURSING

Teaching of General Pathology in the degree courses of Nursing and Obstetric Sciences and Medicine and Surgery

[2012-2013]

University of Catania

Contract professor

Teaching of General and Clinic Pathology in the degree course of NURSING

Teaching of General Pathology in the degree courses of Nursing and Obstetric Sciences and of Osteopathy

[2012-2017]

University of Catania

Contract professor

Teaching of General and Clinic Pathology in the degree course of NURSING

Teaching of General Pathology in the degree courses of Chemistry and Pharmaceutical Technologies and of Osteopathy

[2017-2020]

UNIVERSITY OF CATANIA

RESEARCHER L.240/10 TYPE A

Teaching of General and Clinic Pathology in the degree course of NURSING

Teaching of General Pathology in the degree courses of Chemistry and Pharmaceutical Technologies and course of Sanitary and Molecular-Cellular Biology.

[2018-2023]

University of Molise

Teaching: Seminar activity on "Infection and Autoimmunity"; "Animal models of autoimmunity"; Legislation on animal models" as part of the PhD in "Translational and Clinical Medicine"

[2021-2024]

UNIVERSITY OF CATANIA

RESEARCHER L.240/10 TYPE B

Teaching of General Pathology in the degree courses of Chemistry and Pharmaceutical Technologies, course of Biotechnologies, course of Occupational therapy, course of Biomedical laboratory techniques

[2024-to date]

UNIVERSITY OF CATANIA

Associate Professor of General Pathology

Teaching of General Pathology in the degree courses of Chemistry and Pharmaceutical Technologies, course of Biotechnologies, course of Occupational therapy

NATIONAL ACADEMIC COLLABORATION

Department of Clinical Sciences and Community Health, University of Milan, Istituto G. Pini and IRCCS Istituto Auxologico, Italiano, Milan, Italy.

Department of Clinical and Experimental Medicine and Pharmacology, Torre Biologica, Policlinico Universitario, Messina, Italy.

Department of Health and Medical Sciences "V. Tiberio" Università degli Studi del Molise, 8600 Campobasso, Italy.

IRCCS Centro Neurolesi 'Bonino-Pulejo', I-98124 Messina, Italy.

IRCCS Neuromed, Località Camerelle, 86077 Pozzilli, Italy.

NATIONAL COLLABORATIONS WITH BIOTECHNOLICAL AND PHARMACEUTICALS COMPANIES

Department of Research Neurology in vivo pharmacology, Merck-Serono Ivrea, Colletterto-Giacosa, Torino, Italy.

INTERNATIONAL ACCADEMIC COLLABORATIONS

Institute for Biological Research "Sinisa Stankovic", Università di Belgrado.

Institute for Inflammation Research (IIR), Rigshospitalet University Hospital, Copenhagen, Denmark.

Department of Behavior Neurobiology, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria

INTERNATIONAL COLLABORATIONS WITH BIOTECHNOLICAL AND PHARMACEUTICALS COMPANIES

TherapyX , Buffalo, NY, USA.

Harbor Biosciences, 9171 Towne Centre Drive, Suite 180, San Diego, CA 92122, USA.

Hollis-Eden Pharmaceuticals, 4435 Eastgate Mall, Suite 400, San Diego, CA 92121, USA.

Alfama, Lda., Taguspark, Porto Salvo.

Inovio Pharmaceuticals, Inc., Blue Bell, PA, USA.

MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany.

Numab Therapeutics AG, Bachtobelstrasse 5, CH-8810 Horgen, Switzerland

PARTICIPATION IN CONFERENCES

[May 29-30, 2013] Invited Speaker - FISM ANNUAL SCIENTIFIC CONGRESS

Lecture: Epigenetic Treatment with the Hypomethylating Compound 5-aza-2-deoxycytidine in Animal Models of Multiple Sclerosis

[December 13, 2014] Invited Speaker - ITALIAN SOCIETY OF APPLIED BIOLOGY

Theoretical-Practical Training Course - "Autoimmune Diseases: Current Affairs and Perspectives" - Lecture: Animal Models of Autoimmunity

[October 5-7, 2017] Invited Speaker - 22nd World Congress on Advances in Oncology & the 20th Symposium on Molecular Medicine, Athens, Greece

Lecture: Evaluation of the PI3K/AKT/mTOR Pathway in Multiple Sclerosis

[September 10-13, 2025] Invited Speaker - 21st National Congress of the Italian Society for Neuroscience (SINS), Pisa, Italy

Lecture title: New pharmacological approaches in preclinical models of multiple sclerosis

[November 6-8, 2025] Moderator - 30th International Conference on Molecular Medicine, Catania, Italy

Session title: Molecular and Translational Insights in Neuroprotection, CNS Disorders, and the Gut–Brain Axis

LISTS OF PUBLICATIONS AND PATENTS

2025

- 1) Nicoletti GRP, Mangano K, Nicoletti F, Cavalli E. From Elixirs to Geroscience: A Historical and Molecular Perspective on Anti-Aging Medicine. *Molecules*. 2025 Dec 10;30(24):4728. doi: 10.3390/molecules30244728.
- 2) Santonocito D, Greco G, Sarpietro MG, Schoubben A, Sciacca C, Romeo G, Mangano K, Puglia C. Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study. *Int J Mol Sci*. 2025 Dec 7;26(24):11827. doi: 10.3390/ijms262411827.
- 3) Leone GM, Scuderi G, Fagone P, Mangano K. Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future. *Int J Mol Sci*. 2025 Nov 15;26(22):11055. doi: 10.3390/ijms262211055.
- 4) Scuderi G, Mijatovic S, Maksimovic-Ivanic D, Di Rosa M, Muñoz-Valle JF, Vizcaíno-Quirarte AM, Leone GM, Mangano K, Fagone P, Nicoletti F. Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer. *Genes (Basel)*. 2025 Oct 3;16(10):1170. doi: 10.3390/genes16101170.
- 5) Saita MG, Spitaleri F, Mangano K, Aleo D, Patti A. Synergic Effect of Methyl- β -Cyclodextrin and Hydrophilic Polymers on Nepafenac Solubilization: Development of a 0.3% Ophthalmic Solution. *Molecules*. 2025 Jul 23;30(15):3090.
- 6) Scuderi G, Mangano K, Leone GM, Fagone P, Nicoletti F. TCF3 and ID3 Regulate TSPAN32 Expression in Burkitt Lymphoma. *Scand J Immunol*. 2025 Jul;102(1):e70040.

- 7) Mangano K, Quatrocchi C, Ajello K, Pagani S, Alton G, Longo L, Gerloni M. A rifamycin SV in situ gelling formulation for the treatment of pouchitis. *Drug Deliv Transl Res.* 2025 Feb 13.
- 8) Scuderi G, Mangano K, Petralia MC, Basile MS, Di Raimondo F, Fagone P, Nicoletti F. Comprehensive Analysis of TSPAN32 Regulatory Networks and Their Role in Immune Cell Biology. *Biomolecules.* 2025 Jan 11;15(1):107.

2024

- 9) Mangano K, Munoz-Valle JF, Palafox-Sánchez CA, Petralia MC, Leone GM, Fagone P, Nicoletti F. Tetraspanin32 (TSPAN32) is downregulated in rheumatoid arthritis: Evidence from animal models and patients. *Scand J Immunol.* 2024 Dec;100(6):e13410. doi: 10.1111/sji.13410. Epub 2024 Sep 27.
- 10) Mangano K, Diamantopoulos A, Vallianou NG, Stratigou T, Panagopoulos F, Kounatidis D, Dalamaga M, Fagone P, Nicoletti F. Serum and urinary levels of MIF, CD74, DDT and CXCR4 among patients with type 1 diabetes mellitus, type 2 diabetes and healthy individuals: Implications for further research. *Metabol Open.* 2024 Sep 15;24:100320. doi: 10.1016/j.metop.2024.100320. eCollection 2024 Dec.
- 11) Fagone P, Mangano K, Nicoletti F. The emerging role of Tetraspanin 32 in autoimmune diseases: from discovery to relevant theranostics? *Expert Opin Ther Targets.* 2024 Aug;28(8):655-658.
- 12) Leone GM, Mangano K, Caponnetto S, Fagone P, Nicoletti F. Identification of Poliovirus Receptor-like 3 Protein as a Prognostic Factor in Triple-Negative Breast Cancer. *Cell.* 2024 Aug 3;13(15):1299.
- 13) Fagone P, Mangano K, Basile MS, Munoz-Valle JF, Perciavalle V, Nicoletti F, Bendtzen K. Evaluation of Toll-like Receptor 4 (TLR4) Involvement in Human Atrial Fibrillation: A Computational Study. *Genes (Basel).* 2024 May 16;15(5):634. doi: 10.3390/genes15050634.
- 14) Abarova S, Alexova R, Dragomanova S, Solak A, Fagone P, Mangano K, Petralia MC, Nicoletti F, Kalfin R, Tancheva L. Emerging Therapeutic Potential of Polyphenols from *Geranium sanguineum* L. in Viral Infections, Including SARS-CoV-2. *Biomolecules.* 2024 Jan 19;14(1):130.

2023

- 15) Ferhat M, **Mangano K**, Mirkina I, Mayer J, Rossmueller G, Schinagl A, Kerschbaumer R, Nicoletti F, Thiele M, Landlinger C. The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis. *Eur J Pharmacol.* 2023 Oct 5;956:175997.
- 16) Guido G, **Mangano K**, Tancheva L, Kalfin R, Leone GM, Saraceno A, Fagone P, Nicoletti F, Petralia MC. Evaluation of Cell-Specific Alterations in Alzheimer's Disease and Relevance of In Vitro Models. *Genes (Basel).* 2023 Dec 7;14(12):2187
- 17) Fagone P, Piombino E, **Mangano K**, De Pasquale R, Nicoletti F, Caltabiano R. Evaluation of the Involvement of Heme Oxygenase-1 Expression in Discoid Lupus Erythematosus Lesions. *Antioxidants (Basel).* 2023 Jun 27;12(7):1352.
- 18) **Mangano K**, Petralia MC, Bella R, Pennisi M, Muñoz-Valle JF, Hernández-Bello J, Nicoletti F, Fagone P. Transcriptional upregulation of galectin-3 in multiple sclerosis. *Immunol Res.* 2023 Dec;71(6):950-958.
- 19) Alexova R, Alexandrova S, Dragomanova S, Kalfin R, Solak A, Mehan S, Petralia MC, Fagone P, **Mangano K**, Nicoletti F, Tancheva L. Anti-COVID-19 Potential of Ellagic Acid and Polyphenols of *Punica granatum L.* *Molecules.* 2023 Apr 27;28(9):3772.
- 20) Leone GM, **Mangano K**, Petralia MC, Nicoletti F, Fagone P. Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. *J Clin Med.* 2023 Feb 17;12(4):1630.
- 21) Aleksandrova S, Alexova R, Dragomanova S, Kalfin R, Nicoletti F, Fagone P, Petralia MC, **Mangano K**, Tancheva L. Preventive and Therapeutic Effects of *Punica granatum L.* Polyphenols in Neurological Conditions. *Int J Mol Sci.* 2023 Jan 17;24(3):1856.

2022

- 22) Petralia MC, Nicoletti F, Tancheva L, Kalfin R, Fagone P, **Mangano K**. Gene Co-Expression Network Modular Analysis Reveals Altered Immune Mechanisms in HIV-HAND. *Brain Sci.* 2022 Oct 12;12(10):1378.
- 23) Petralia MC, **Mangano K**, Quattropiani MC, Lenzo V, Nicoletti F, Fagone P. Computational Analysis of Pathogenetic Pathways in Alzheimer's Disease and Prediction of Potential Therapeutic Drugs. *Brain Sci.* 2022 Jun 24;12(7):827.

- 24) Fagone P, **Mangano K**, Martino G, Quattropiani MC, Pennisi M, Bella R, Fisicaro F, Nicoletti F, Petralia MC. Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs. *Genes (Basel)*. 2022 Apr 15;13(4):703.
- 25) Nicoletti F, Hammer L, Furtado S, **Mangano K**, Mathiowitz E, Green B, Auci DL. Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis. *Inflamm Bowel Dis*. 2022 Mar 2;28(3):455-465.

2021

- 26) Dragomanova S, Miteva S, Nicoletti F, **Mangano K**, Fagone P, Pricoco S, Staykov H, Tancheva L. Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. *Antioxidants (Basel)*. 2021 Aug 16;10(8):1294
- 27) Petralia MC, Ciurleo R, Bramanti A, Bramanti P, Saraceno A, **Mangano K**, Quattropiani MC, Nicoletti F, Fagone P. Transcriptomic Data Analysis Reveals a Down-Expression of Galectin-8 in Schizophrenia Hippocampus. *Brain Sci*. 2021 Jul 23;11(8):973.
- 28) Fagone, P., **Mangano, K.**, Di Marco, R., Muñoz-Valle, J.F., Nicoletti, F. Altered expression of tspan32 during b cell activation and systemic lupus erythematosus. *Genes*, 2021, 12(6), 931
- 29) Cutuli MA, Guarnieri A, Pietrangelo L, Magnifico I, Venditti N, Recchia L, **Mangano K**, Nicoletti F, Di Marco R, Petronio G. Potential Mucosal Irritation Discrimination of Surface Disinfectants Employed against SARS-CoV-2 by *Limacus flavus* Slug Mucosal Irritation Assay. *Biomedicines*. 2021 Apr 14;9(4):424
- 30) Lombardo SD, Basile MS, Ciurleo R, Bramanti A, Arcidiacono A, **Mangano K**, Bramanti P, Nicoletti F, Fagone P. *Genes (Basel)*. A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy. 2021 Apr 9;12(4):543.
- 31) Scillato M, Spitale A, Mongelli G, Privitera GF, **Mangano K**, Cianci A, Stefani S, Santagati M. Antimicrobial properties of *Lactobacillus* cell-free supernatants against multidrug-resistant urogenital pathogens. *Microbiologyopen*. 2021 Feb;10(2):e1173.
- 32) Sánchez-Zuno GA, Matuz-Flores MG, González-Estevez G, Nicoletti F, Turrubiates-Hernández FJ, **Mangano K**, Muñoz-Valle JF. A review: Antibody-

dependent enhancement in COVID-19: The not so friendly side of antibodies. *Int J Immunopathol Pharmacol*. 2021 Jan-Dec;35:20587384211050199.

- 33) Caltabiano, R., De Pasquale, R., Piombino, E., **Mangano, K.**, Fagone, P. Macrophage Migration Inhibitory Factor (MIF) and Its Homologue d-Dopachrome Tautomerase (DDT) Inversely Correlate with Inflammation in Discoid Lupus Erythematosus. *Molecules* (Basel, Switzerland), 2021, 26(1)

2020

- 34) Magnifico I, Petronio G, Venditti N, Cutuli MA, Pietrangelo L, Vergalito F, **Mangano K**, Zella D, Di Marco R. Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy? *Pharmaceuticals* (Basel). 2020 Nov 22;13(11):411. doi: 10.3390/ph13110411. I.F. 4,286
- 35) Schumann S, Kaiser A, Nicoletti F, **Mangano K**, Fagone P, van Wijk E, Yan Y, Schulz P, Ludescher B, Niedermaier M, von Wegerer J, Rauch P, Setz C, Schubert U, Brysch W. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. *Int J Mol Sci*. 2020 Nov 20;21(22):8803. doi: 10.3390/ijms21228803. I.F. 4,556
- 36) Lombardo SD, Bramanti A, Ciurleo R, Basile MS, Pennisi M, Bella R, **Mangano K**, Bramanti P, Nicoletti F, Fagone P. Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. *Oncol Lett*. 2020 Dec;20(6):332. doi: 10.3892/ol.2020.12195. Epub 2020 Oct 7. I.F. 2,311
- 37) Pesce A, Ciurleo R, Bramanti A, Armeli Iapichino EC, Petralia MC, Magro GG, Fagone P, Bramanti P, Nicoletti F, **Mangano K**. Effects of Combined Administration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis. *Molecules*. 2020 Sep 20;25(18):4310. doi: 10.3390/molecules25184310. I.F. 3,267
- 38) Lombardo SD, Battaglia G, Petralia MC, **Mangano K**, Basile MS, Bruno V, Fagone P, Bella R, Nicoletti F, Cavalli E. Transcriptomic Analysis Reveals Abnormal Expression of Prion Disease Gene Pathway in Brains from Patients with Autism Spectrum Disorders. *Brain Sci*. 2020 Mar 29;10(4):200. I.F. 3,332
- 39) Basile MS, Battaglia G, Bruno V, **Mangano K**, Fagone P, Petralia MC, Nicoletti F, Cavalli E. The Dichotomic Role of Macrophage Migration Inhibitory Factor in

Neurodegeneration. *Int J Mol Sci.* 2020 Apr 24;21(8):3023. doi: 10.3390/ijms21083023. I.F. 4,556

- 40) Basile MS, Mazzon E, **Mangano K**, Pennisi M, Petralia MC, Lombardo SD, Nicoletti F, Fagone P, Cavalli E. Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. *Brain Sci.* 2020 Jan 17;10(1):52. I.F. 3,332
- 41) Cavalli E, Battaglia G, Basile MS, Bruno V, Petralia MC, Lombardo SD, Pennisi M, Kalfin R, Tancheva L, Fagone P, Nicoletti F, **Mangano K**. Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. *Brain Sci.* 2020 Mar 13;10(3):166. doi: 10.3390/brainsci10030166. I.F. 3,332
- 42) Cavalli E, Ciurleo R, Petralia MC, Fagone P, Bella R, **Mangano K**, Nicoletti F, Bramanti P, Basile MS. Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets? *Molecules.* 2020 Mar 6;25(5):1194. I.F. 3,267
- 43) Christodoulou MS, Nicoletti F, **Mangano K**, Chiacchio MA, Facchetti G, Rimoldi I, Beccalli EM, Giofrè S. Novel 3,3-disubstituted oxindole derivatives. Synthesis and evaluation of the anti-proliferative activity. *Bioorg Med Chem Lett.* 2020 Jan 15;30(2):126845. I.F. 3,073
- 44) Petralia MC, Mazzon E, Basile MS, Cutuli M, Di Marco R, Scandurra F, Saraceno A, Fagone P, Nicoletti F, **Mangano K**. Effects of Treatment with the Hypomethylating Agent 5-aza-2'-deoxycytidine in Murine Type II Collagen-Induced Arthritis. *Pharmaceuticals (Basel).* 2019 Nov 27;12(4):174. doi: 10.3390/ph12040174. I.F. 4,286
2019
- 45) Lombardo SD, Mazzon E, **Mangano K**, Basile MS, Cavalli E, Mammana S, Fagone P, Nicoletti F, Petralia MC. Transcriptomic Analysis Reveals Involvement of the Macrophage Migration Inhibitory Factor Gene Network in Duchenne Muscular Dystrophy. *Genes (Basel).* 2019 Nov 18;10(11):939.
doi: 10.3390/genes10110939. I.F. 3,759
- 46) Cavalli E, Mazzon E, Mammana S, Basile MS, Lombardo SD, **Mangano K**, Bramanti P, Nicoletti F, Fagone P, Petralia MC. Overexpression of Macrophage

- Migration Inhibitory Factor and Its Homologue D-Dopachrome Tautomerase as Negative Prognostic Factor in Neuroblastoma. *Brain Sci.* 2019 Oct 19;9(10):284. doi: 10.3390/brainsci9100284. I.F. 3,332
- 47) Cavalli E, Mazzon E, Basile MS, **Mangano K**, Di Marco R, Bramanti P, Nicoletti F, Fagone P, Petralia MC. Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis. *Medicina (Kaunas)*. 2019 Oct 1;55(10). I.F. 1,205
- 48) Lombardo SD, Mazzon E, Basile MS, Campo G, Corsico F, Presti M, Bramanti P, **Mangano K**, Petralia MC, Nicoletti F, Fagone P. Modulation of Tetraspanin 32 (TSPAN32) Expression in T Cell-Mediated Immune Responses and in Multiple Sclerosis. *Int J Mol Sci.* 2019 Sep 4;20(18) I.F. 4,556
- 49) Lombardo SD, Presti M, **Mangano K**, Petralia MC, Basile MS, Libra M, Candido S, Fagone P, Mazzon E, Nicoletti F, Bramanti A. Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. *Brain Sci.* 2019 Aug 31;9(9) I.F. 3,332
- 50) **Mangano K**, Lanteri R, Basile MS, Bellavia N, Latino R, Messina D, Fagone P, Colletti G, Nania R, Caltabiano R, Di Marco R, Di Cataldo A. Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. *Int J Immunopathol Pharmacol.* 2019 Jan-Dec;33:2058738419862736 I.F. 2,209
- 51) Fagone P, Mazzon E, Mammana S, Di Marco R, Spinasantà F, Basile MS, Petralia MC, Bramanti P, Nicoletti F, **Mangano K**. Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment. *Mol Med Rep.* 2019 Jul;20(1):678-684. I.F. 2,1
- 52) Nicoletti F, Mazzon E, Fagone P, **Mangano K**, Mammana S, Cavalli E, Basile MS, Bramanti P, Scalabrino G, Lange A, Curtin F. Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF. *J Neuroimmunol.* 2019 May 8;332:224-232. [Epub ahead of print] I.F. 3,125
- 53) Paskaš S, Krajnović T, Basile MS, Dunderović D, Cavalli E, **Mangano K**, Mammana S, Al-Abed Y, Nicoletti F, Mijatović S, Maksimović-Ivanić D.

Senescence as a main mechanism of Ritonavir and Ritonavir-NO action against melanoma. *Mol Carcinog*. 2019 Apr 17. [Epub ahead of print] I.F. 3,825

- 54) Basile MS, Fagone P, **Mangano K**, Mammana S, Magro G, Salvatorelli L, Li Destri G, La Greca G, Nicoletti F, Puleo S, Pesce A. KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. *Cancers (Basel)*. 2019 Feb 19;11(2). I.F. 6,126

2018

- 55) Fagone P, Mazzon E, Chikovani T, Saraceno A, Mammana S, Colletti G, **Mangano K**, Bramanti P, Nicoletti F. Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. *J Neuroimmunol*. 2018 Aug 15;321:41-48. I.F. 3,125

- 56) Fagone P, Mazzon E, Cavalli E, Bramanti A, Petralia MC, **Mangano K**, Al-Abed Y, Bramati P, Nicoletti F. Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences. *J Neuroimmunol*. 2018 Jun 15 I.F. 3,125

- 57) **Mangano K**, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P, Nicoletti F. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. *Oncotarget*. 2018 Apr 3;9(25):17951-17970. I.F. 3,710

- 58) Mammana S, Bramanti P, Mazzon E, Cavalli E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F, **Mangano K**. Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. *Oncotarget*. 2018 Jan 3;9(9):8263-8277. IF 5,17

2017

- 59) Inturri R, **Mangano K**, Santagati M, Intrieri M, Di Marco R, Blandino G. Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production. *Curr Pharm Biotechnol*. 2017;18(11):883-889. IF 2,46

- 60) Genovese C, Davinelli S, **Mangano K**, Tempera G, Nicolosi D, Corsello S, Vergalito F, Tartaglia E, Scapagnini G, Di Marco R. Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent

urinary tract infections. *J Chemother.* 2017 Oct 27;1-8. IF: 1,661

- 61) **Mangano K**, Cavalli E, Mammana S, Basile MS, Caltabiano R, Pesce A, Puleo S, Atanasov AG, Magro G, Nicoletti F, Fagone P. Involvement of the Nrf2/HO-1/CO axis and therapeutic intervention with the CO-Releasing Molecule CORM-A1, in a murine model of Autoimmune Hepatitis. *J Cell Physiol.* 2017 Oct 15. IF: 5,546
- 62) **Mangano K**, Vergalito F, Mammana S, Mariano A, De Pasquale R, Meloscia A, Bartollino S, Guerra G, Nicoletti F, Di Marco R. Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. *Exp Ther Med.* 2017 Sep;14(3):2439-2444. IF: 1,785
- 63) Nikolic I, Stojanovic I, Vujicic M, Fagone P, **Mangano K**, Stosic-Grujicic S, Nicoletti F, Saksida T (2017). Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. *Immunobiology.* 2017 Feb;222(2):272-279. IF: 2,72

2016

- 64) Signorelli SS, Anzaldi M, Libra M, Navolanic PM, Malaponte G, **Mangano K**, Quattrocchi C, Di Marco R, Fiore V, Neri S. Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease: Results of a Cohort Study. *Angiology.* 2016 Oct;67(9):870-4. IF: 3.085
- 65) Fagone P, **Mangano K**, Di Marco R, Touil-Boukoffa C, Chikovan T, Signorelli S, Lombardo GA, Patti F, Mammana S, Nicoletti F. Expression of DNA methylation genes in secondary progressive multiple sclerosis. *J Neuroimmunol.* 2016 Jan 15;290:66-9 IF: 2,720
- 66) Fagone P, **Mangano K**, Pesce A, Portale TR, Puleo S, Nicoletti F. Emerging therapeutic targets for the treatment of hepatic fibrosis. *Drug Discov Today.* 2016 21(2):369-75. IF: 6.369

2015

- 67) Fagone P, **Mangano K**, Mammana S, Pesce A, Caltabiano R, Giorlandino A, Portale TR, Cavalli E, Lombardo GA, Coco M, Puleo S, Nicoletti F. Identification of novel targets for the diagnosis and treatment of liver fibrosis. *Int J Mol Med* 2015; 36: 747-52 IF: 2,341
- 68) Conway TF, Hammer L, Furtado S, Mathiowitz E, Nicoletti F, **Mangano K**, Egilmez NK, Auci DL. Oral Delivery of Particulate Transforming Growth Factor

- Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease. *J Crohns Colitis*. . 2015 Aug;9(8):647-58. IF: 5.813
- 69) Fagone P, **Mangano K**, Quattrocchi C, Cavalli E, Mammana S, Lombardo GA, Pennisi V, Zocca MB, He M, Al-Abed Y, Nicoletti F Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir. *Basic Clin Pharmacol Toxicol*. 2015 Nov;117(5):306-15. IF: 3.176
- 70) Fagone P, **Mangano K**, Mammana S, Cavalli E, Di Marco R, Barcellona ML, Salvatorelli L, Magro G, Nicoletti F. Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. *Clin Immunol*. 2015 Feb 19;157(2):198-204. IF: 3,990
- 2014
- 71) Celasco G, Moro L, Aiello C, **Mangano K**, Milasi A, Quattrocchi C, DI Marco R. Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties. *Biomed Rep*. 2014 Jul;2(4):559-563. Epub 2014 May 8.
- 72) Momčilović M, **Mangano K**, Jevtić B, Mammana S, Stošić-Grujičić S, Nicoletti F, Miljković D. Saquinavir-NO inhibits IL-6 production in macrophages. *Basic Clin Pharmacol Toxicol*. 2014 Dec;115(6):499-506. IF: 3.176
- 73) **Mangano K**, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, Rosa MD, Malaguarnera L, Coco M, Magro G, Marco RD, Nicoletti F. Hypomethylating Agent 5-Aza-2'-deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models. *J Cell Physiol*. 2014 Dec;229(12):1918-25. IF: 4.08
- 74) Fagone P, Muthumani K, **Mangano K**, Magro G, Meroni PL, Kim JJ, Sardesai NY, Weiner DB, Nicoletti F. VGX-1027 modulates genes involved in the LPS-induced TLR-4 activation and in a murine model of Systemic Lupus Erythematosus. *Immunology*. 2014 Aug;142(4):594-602. IF: 3,701
- 75) Fagone P, **Mangano K**, Mammana S, Quattrocchi C, Magro G, Coco M, Imene S, Di Marco R, Nicoletti F. Acceleration of SLE-like syndrome development in NZBxNZW F1 mice by beta-glucan. *Lupus*. 2014 Apr;23(4):407-11. IF: 2,454
- 76) Nikolic I, Saksida T, **Mangano K**, Vujicic M, Stojanovic I, Nicoletti F, Stosic-Grujicic S. Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. *Diabetologia*. 2014 May;57(5):980-90. IF: 6,080

2013

- 77) Saksida T, Miljkovic D, Timotijevic G, Stojanovic I, Mijatovic S, Fagone P, **Mangano K**, Mammana S, Farina C, Ascione E, Maiello V, Nicoletti F, Stosic-Grujicic S. Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. *J Neuroimmunol*. 2013 Sep 15;262(1-2):72-8. IF: 2,720
- 78) Fagone P, Patti F, **Mangano K**, Mammana S, Coco M, Touil-Boukoffa C, Chikovani T, Di Marco R, Nicoletti F. Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. *J Neuroimmunol*. 2013 Aug 15;261(1-2):82-6. IF: 2,720
- 79) Petković F, Blaževski J, Momčilović M, Timotijević G, Zocca MB, Mijatović S, Maksimović-Ivanić D, **Mangano K**, Fagone P, Stošić-Grujičić S, Nicoletti F, Miljković D. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. *J Neuroimmunol*. 2013 Jun 15;259(1-2):55-65. IF: 2,720
- 80) Signorelli SS, Anzaldi M, Fiore V, Candido S, Di Marco R, **Mangano K**, Quattrocchi C, Neri S. Neopterin: a potential marker in chronic peripheral arterial disease. *Mol Med Rep*. 2013 Jun;7(6):1855-8. IF: 1,692
- 81) Giunta G, Giuffrida L, Mangano K, Fagone P, Cianci A. Influence of lactoferrin in preventing preterm delivery: a pilot study. *Mol Med Rep*. 2013 Apr;7(4):1366. IF: 1,692
- 82) Di Rosa M, **Mangano K**, De Gregorio C, Nicoletti F, Malaguarnera L. Association of chitotriosidase genotype with the development of non-alcoholic fatty liver disease. *HEPATOLOGY RESEARCH*, 2013 Mar;43(3):267-75 IF: 2,735
- 83) D'Amico F, Skarmoutsou E, **Mangano K**, Malaponte G, Mazzarino MC. Isoproterenol modulates matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor-2 (TIMP-2) in rat parotid gland. *Archives of Oral Biology*. 2013Apr;58(4):370-6 IF: 1,735

2012

- 84) Fagone P, Donia M, **Mangano K**, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA, Nicoletti F. Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells. *BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY* 2013 Jan;112(1):63-9 IF: 2.377
- 85) Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, **Mangano K**, Zocca MB, Al-Abed Y, McCubrey JA,

- Nicoletti F (2012). Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. *CELL CYCLE* 2012 11, p. 1174-1182 IF: 4,565
- 86) Mojic M1, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. *Mol Pharmacol.* 2012 Oct;82(4):700-10. Epub 2012 Jul 13. IF: 3.922
- 87) **Mangano K**, Fagone P, Di Mauro M, Ascione E, Maiello V, Milicic T, Jotic A, Lalic NM, Saksida T, Stojanovic I, Selmi C, Farina C, Stosic-Grujicic S, Meroni P, Nicoletti F. The immunobiology of apotransferrin in type 1 diabetes. *CLINICAL AND EXPERIMENTAL IMMUNOLOGY* 2012 169, p. 244-252 IF: 3,41
- 88) Fagone P, **Mangano K**, Coco M, Perciavalle V, Garotta G, Romao CC, Nicoletti F . Therapeutic potential of carbon monoxide in multiple sclerosis. *CLINICAL AND EXPERIMENTAL IMMUNOLOGY* 2012 167, p. 179-187. IF: 3,41
- 89) Donia M, **Mangano K**, Fagone P, De Pasquale R, Dinotta F, Coco M, Padron J, Al-Abed Y, Giovanni Lombardo GA, Maksimovic-Ivanic D, Mijatovic S, Zocca MB, Perciavalle V, Stosic-Grujicic S, Nicoletti F. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. *ONCOLOGY REPORTS* 2012 Aug;28(2):682-8 IF: 2,301

2011

- 90) Mijatovic Sanja, Maksimovic-Ivanic Danijela, Mojic Marija, Timotijevic Gordana, Miljkovic Djordje, **Mangano K**, Donia Marco, Di Cataldo Antonio, Al-Abed Yousef, Cheng Kai Fan, Stosic-Grujicic Stanislava, Nicoletti Ferdinando (2011). Cytotoxic and Immune-Sensitizing Properties of Nitric Oxide-Modified Saquinavir in iNOS-Positive Human Melanoma Cells. *JOURNAL OF CELLULAR PHYSIOLOGY.* 2011, 226:1803-1812 IF: 4.080
- 91) Kosiewicz Michele M., Auci Dominick L., Fagone Paolo, **Mangano K**, Caponnetto Salvatore, Tucker Colleen F., Azeem Nabeel, White Steven K., Frincke James M., Reading Christopher L., Nicoletti Ferdinando (2011). HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse. *EUROPEAN JOURNAL OF PHARMACOLOGY.* 2011, 658:257-262 IF: 2,896

- 92) Ahlem Clarence N., Page Theodore M., Auci Dominick L., Kennedy Michael R., **Mangano K**, Nicoletti Ferdinando, Ge Yu, Huang Yujin, White Steven K., Villegas Sonia, Conrad Douglas, Wang Angela, Reading Christopher L., Frincke James M. Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. *STEROIDS* 2011, 76: 145-155 IF: 2,282
- 93) Nicoletti Alessandra, Fagone Paolo, Donzuso Giulia, **Mangano K**, Dibilio Valeria, Caponnetto Salvatore, Bendtzen Klaus, Zappia Mario, Nicoletti Ferdinando. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. *CYTOKINE* 2011, 55: 165-167 IF: 3.488
- 94) Donia Marco, Anzaldi Massimiliano, Di Marco Roberto, Libra Massimo, **Mangano K**, Fagone Paolo, Galvagna Salvatore, Di Gregorio Pietro, Nicoletti Ferdinando. Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* 2011, 28: 437-442 IF: 2,341
- 95) Fagone P., **Mangano K**, Quattrocchi C., Motterlini R., Di Marco R., Magro G., Penacho N., Romao C. C., Nicoletti F. Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*. 2011, 163:368-374 IF: 3,410
- 2010
- 96) D'Amico Fabio, Skarmoutsou Evangelia, Mangano K, Malaponte Grazia, Stivala Franca, Mazzarino Maria Clorinda. Expression and localization of prominin-1 in isoproterenol-treated rat parotid gland. *INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE* 2010, 26: 505-510 IF: 2,341
- 97) Conrad Douglas, Wang Angela, Pieters Raymond, Nicoletti Ferdinando, **Mangano K**, van Heeckeren Anna M., White Steven K., Frincke James M., Reading Christopher L., Stickney Dwight, Auci Dominick L. HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression. *JOURNAL OF INFLAMMATION* 2010 Oct 30;7:52 IF: 2,714
- 98) Auci Dominick L., **Mangano K**, Destiche Daniel, White Steven K., Huang Yujin, Boyle David, Frincke James, Reading Christopher L., Nicoletti Ferdinando (2010). Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2010, 25: 625-633 IF: 2,341

- 99) Donia M., **Mangano K**, Quattrocchi C., Fagone P., Signorelli S., Magro G., Sfacteria A., Bendtzen K., Nicoletti F. Specific and Strain-Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents. SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2010, 72:396-407 IF: 2.256
- 100) **Mangano K**, Nicoletti A., Patti F., Donia M., Malaguarnera L., Signorelli S., Magro G., Muzio V., Greco B., Zaratini P., Meroni P., Zappia M., Nicoletti F. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2010, 159:159-168 IF: 3,41
- 101) Nicoletti F, Auci DL, **Mangano K**, Flores-Riveros J, Villegas S, Frincke JM, Reading CL and Offner H. 5-Androstenediol Ameliorates Pleurisy, Septic Shock, and Experimental Autoimmune Encephalomyelitis in Mice. AUTOIMMUNE DISEASES. 2010 May 18

2009

- 102) Nicoletti F., Conrad D., Wang A., Pieters R., **Mangano K**, van Heeckeren A., White S. K., Frincke J., Reading C. L., Auci D. L., Stickney D. 16 alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2009, 158: 308-316 IF: 3,41
- 103) Alleva David, Nicoletti Ferdinando, **Mangano K**, Tucker Colleen, Azeem Nabeel, Kosiewicz Michele, Hein Nancy, Ticsay Rudy, Jen Kai Yu, McNeeley Patricia, Wang Tianlun, White Steven, Reading Christopher, Frincke James, Auci Dominick. Efficacy of a Novel Synthetic Steroid, TRIOLEX (TM) (17 alpha-ethynyl-5-androsten-3 beta, 7 beta, 17 beta-triol), in Spontaneous Autoimmune Diabetes in the Non-Obese Diabetic (NOD) Mouse. CLINICAL IMMUNOLOGY. 2009, 131: S75 IF: 3,990
- 104) Ahlem C., Auci D., **Mangano K**, Reading C., Frincke J., Stickney D., Nicoletti F., BE Shoenfeld Y Gershwin ME. HE3286: A Novel Synthetic Steroid as an Oral Treatment for Autoimmune Disease. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2009, 1173: 781-790 IF: 4,706
- 105) Nicoletti F., Lamenta C., Donati S., Spada M., Ranazzi A., Cacopardo B.,

Mangano K, Belardelli F., Perno C., Aquaro S. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2009, 155: 28-34 IF: 3,41

106) Dujmovic Irena, **Mangano K**, Pekmezovic Tatjana, Quattrocchi Cinzia, Mesaros Sarlota, Stojasavljevic Nebojsa, Nicoletti Ferdinando, Drulovic Jelena. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. JOURNAL OF NEUROIMMUNOLOGY. 2009, 207:101-106 IF: 2,720

107) Maksimovic-Ivanic Danijela, Mijatovic Sanja, Miljkovic Djordje, Harhaji-Trajkovic Ljubica, Timotijevic Gordana, Mojic Marija, Dabideen Darrin, Cheng Kai Fan, McCubrey James A., **Mangano K**, Al-Abed Yousef, Libra Massimo, Garotta Gianni, Stosic-Grujicic Stanislava, Nicoletti Ferdinando. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. MOLECULAR CANCER THERAPEUTICS. 2009, 8:1169-1178 IF: 5,764

108) Donia Marco, Mijatovic Sanja, Maksimovic-Ivanic Danijela, Miljkovic Djordje, **Mangano K**, Tumino Salvatore, Biondi Antonio, Basile Francesco, Al-Abed Yousef, Stosic-Grujicic Stanislava, Nicoletti Ferdinando. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. EUROPEAN JOURNAL OF PHARMACOLOGY. 2009, 615: 228-233 IF: 2,896

109) Donia Marco, **Mangano K**, Amoroso Alfredo, Mazzarino Maria Clorinda, Imbesi Rosa, Castrogiovanni Paola, Coco Marinella, Meroni PierLuigi, Nicoletti Ferdinando. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+regulatory T cells. JOURNAL OF AUTOIMMUNITY. 2009, 33: 135-140. IF: 7.641

2008

110) Maksimovic-Ivanic Danijela, Mijatovic Sanja, Harhaji Ljubica, Miljkovic Djordje, Dabideen Darrin, Cheng Kai Fan, **Mangano K**, Malaponte Graziella, Ai-Abed Yousef, Libra Massimo, Garotta Gianni, Nicoletti Ferdinando, Stosic-Grujicic Stanislava. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-

isoxazole acetic acid-nitric oxide in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS. 2008, 7: 510-520 IF: 5,764

111) **Mangano K**, Sardesai N. Y., Quattrocchi C., Mazzon E., Cuzzocrea S., Bendtzen K., Meroni P. L., Kim J. J., Nicoletti F. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. BRITISH JOURNAL OF PHARMACOLOGY. 2008, 155: 722-730 IF: 5.491

112) Celasco Giuseppe, Moro Luigi, Bozzella Roberta, **Mangano K**, Quattrocchi Cinzia, Aiello Caterina, Donia Marco, Fagone Paolo, Di Marco Roberto. Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat. DIGESTIVE DISEASES AND SCIENCES. 2008, 53:3170-3175 IF:2,875

113) **Mangano K**, Sardesai N, D'Alcamo M, Libra M, Malaguarnera L, Donia M, Bendtzen K, Meroni P, Nicoletti F. In vitro inhibition of enterobacteria-reactive CD4+CD25-T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. EUROPEAN JOURNAL OF PHARMACOLOGY. 2008, 586: 313-321 IF: 2,896

114) Stosic-Grujicic Stanislava, Stojanovic Ivana, Maksimovic-Ivanic Danijela, Momcilovic Miljana, Popadic Dusan, Harhaji Ljubica, Miljkovic Djordje, Metz Christine, **Mangano K**, Papaccio Gianpacilo, Al-Abed Yousef, Nicolett Ferdinando. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. JOURNAL OF CELLULAR PHYSIOLOGY. 2008, 215: 665-675 IF: 4.080

115) **Mangano K**, Dati Gabriele, Quattrocchi Cinzia, Proietti Lidia, Mazzarino Clorinda, Di Marco Roberto, Bendtzen Klaus, Greco Beatrice, Zaratina Paola, Nicoletti Ferdinando. Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barre syndrome. JOURNAL OF NEUROIMMUNOLOGY. 2008, 196: 107-115 IF: 2,720

2007

116) Stosic-Grujicic Stanislava, Cvetkovic Ivana, **Mangano K**, Fresta Massimo, Maksimovic-Ivanic Danijela, Harhaji Ljubica, Popadic Dusan, Momcilovic Miljana, Miljkovic Djordje, Kim Joseph, Al Abed Yousef, Nicoletti Ferdinando. A potent immunomodulatory compound, (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H

mice. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2007, 320: 1038-1049 IF: 3,867

- 117) Malaponte G., Libra M., Cardile V., Lombardo L., Ligresti G., **Mangano K**, Maksimovic-Ivanic D., Mijatovic S., Al-Abed Y., Mazzarino M. C., Nicoletti F., Stivala F. GIT-27 NO may be a potential therapeutic agent for melanoma treatment by inhibition of the transcription repressor YIN-YANG. NITRIC OXIDE. 2007, 17: S25 IF: 4.181
- 118) Stojanovic Ivana, Cuzzocrea Salvatore, **Mangano K**, Mazzon Emanuela, Miljkovic Djordje, Wang Mingjun, Donia Marco, Al Abed Yousef, Kim Joseph, Nicoletti Ferdinando, Stosic-Grujicic Stanislava, Claesson Mogens. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. CLINICAL IMMUNOLOGY. 2007, 123:311-323 IF: 3,990

2006

- 119) Libra M, **Mangano K**, Anzaldi M, Quattrocchi C, Donia M, Di Marco R, Signorelli S, Scalia G, Zignego AL, De Re V, Mazzarino MC, Nicoletti F. Analysis of interleukin (IL)-1 beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. ONCOLOGY REPORTS. 2006, 15:1305-1308 IF:2,662
- 120) Malaponte G, Libra M, Gangemi P, Bevelacqua V, **Mangano K**, D'Amico F, Mazzarino MC, Stivala F, McCubrey JA, Travali S. Detection of BRAF gene mutation in primary choroidal melanoma tissue. CANCER BIOLOGY & THERAPY. 2006, 5: 225-227 IF: 3,294
- 121) **Mangano K**, Quattrocchi C., Aiello C., Scalia G., Speciale A., Nicoletti G., Di Marco R. (2006). Immunomodulatory properties of cefaclor: In vivo effect on cytokine release and lymphoproliferative response in rats. JOURNAL OF CHEMOTHERAPY. 2006, 18: 641-647 IF: 1,577
- 122) Dati G, Nicoletti F, Di Marco R, **Mangano K**, Greco B, Zaratin P (2006). Therapeutic effects of single administration of Cyclophosphamide in rat experimental autoimmune neuritis, a pre-clinical model of autoimmune peripheral neuropathies. JOURNAL OF NEUROIMMUNOLOGY. 2006, 178: 226 IF: 2,720

2005

- 123) Auci D, Nicoletti F, **Mangano K**, Pieters R, Nierkens S, Morgan L, Offner H,

Frincke J, Reading C, BE Shoenfeld Y Gershwin ME. Anti-inflammatory and immune regulatory properties of 5-androsten-3 beta,17 beta-diol (HE2100), and synthetic analogue HE3204 implications for treatment of autoimmune diseases. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2005, 1051: 730-742 IF: 4,706

124) Nicoletti F, Creange A, Orlikowski D, Bolgert F, **Mangano K**, Metz C, Di Marco R, Al Abed Y. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. JOURNAL OF NEUROIMMUNOLOGY. 2005, 168:168-174 IF: 2,72

2004

125) Di Marco R, **Mangano K**, Quattrocchi C, Amato F, Nicoletti F, Buschard K (2004). Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. APMIS. ACTA PATHOLOGICA, MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA. 2004, 112:651-655 IF: 1.795

126) Iauk L, **Mangano K**, Rapisarda A, Ragusa S, Maiolino L, Musumeci R, Costanzo R, Serra A, Speciale A. Protection against murine endotoxemia by treatment with Ruta Chalepensis L., a plant with anti-inflammatory properties. JOURNAL OF ETHNOPHARMACOLOGY. 2004, 90:267-272 IF: 2,981

2003

127) Di Marco R, **Mangano K**, Quattrocchi C, Musumeci R, Speciale AM, Papaccio G, Buschard K, Bendtzen K, Nicoletti F. Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. CLINICAL IMMUNOLOGY. 2003, 109:266-271 IF: 3,990

2002

128) Besong G, Battaglia G, D'Onofrio M, Di Marco R, Ngomba RT, Storto M, Castiglione M, **Mangano K**, Busceti CL, Nicoletti FR, Bacon K, Tusche M, Valenti O, Conn PJ, Bruno V, Nicoletti F. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. THE JOURNAL OF NEUROSCIENCE. 2002, 22: 5403-5411 IF: 5.988

2001

129) Nicoletti F, Di Marco R, **Mangano K**, Patti F, Reggio E, Nicoletti A, Bendtzen K, Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis.

NEUROLOGY. 2001, 57: 342-344 IF: 7.592

- 130) Nicoletti F, Di Marco R, Sacerdote P, Meroni P, **Mangano K**, Edwards C, Bartorelli A, Bendtzen K, Panerai A. Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*. 2001, 45:1591-1594 IF: 4,302

PATENTS

2015

- 1) Scapagnini G, Di Marco R, Mangano K, Longo Sormani S- Brevetto depositato dal titolo: "COMPOSIZIONE PER PREVENIRE O TRATTARE LA SINDROME DELL'OVAIO POLICISTICO E LA SINTOMATOLOGIA CORRELATA".

2016

- 2) Sferra D, Russo V, Vergalito F, Franceschini D, Mangano K, Scapagnini G, Di Marco R, Longo S - Granted European Patents EP2895180 - COMPOSITION FOR THE PREVENTION AND TREATMENT OF ACUTE AND RECURRENT URINARY TRACT INFECTIONS.

2017

- 3) Vara Salazar YI, Aldaba Arevalo E Nicoletti F, Libra M, Mangano K - European Patents 16382518.5 - 1466 "COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES".

The undersigned declares to be informed, according to Legislative Decree 196/2003, that the above data will be used in the context of the procedure for which this declaration is made.

Catania, Feb 16th 2026

